News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Lawrence Blonde, MD

Articles by Lawrence Blonde, MD

Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

ByRobert A. Bailey, MD,Ujjwala Vijapurkar, PhD,Gary E. Meininger, MD,Marcia F. T. Rupnow, PhD,Lawrence Blonde, MD

December 16th 2014

Participating Faculty: Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

ByRobert A. Bailey, MD,Ujjwala Vijapurkar, PhD,Gary E. Meininger, MD,Marcia F.T. Rupnow, PhD,Lawrence Blonde, MD

December 15th 2014

Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin

ByRobert A. Bailey, MD,C. V. Damaraju, PhD,Silas C. Martin, MS,Gary E. Meininger, MD,Marcia F. T. Rupnow, PhD,Lawrence Blonde, MD

January 25th 2014

State of Diabetes Care in the United States

ByLawrence Blonde, MD

April 1st 2007

New Directions for Type 2 Diabetes Mellitus Management

ByLawrence Blonde, MD

October 1st 2002

Thiazolidinediones in the Treatment of Managed Care Patients with Type 2 Diabetes

ByRam Pathak, MD,Azar Afaq, MD,Lawrence Blonde, MD

October 1st 2002

Latest Updated Articles

Participating Faculty: Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials
December 15th 2014
Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials
December 16th 2014
State of Diabetes Care in the United States
April 1st 2007
Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin
January 25th 2014
New Directions for Type 2 Diabetes Mellitus Management
October 1st 2002
Thiazolidinediones in the Treatment of Managed Care Patients with Type 2 Diabetes
October 1st 2002

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies